plasma kallikrein has been prepared in rabbits with kallikrein further purified to remove gamma globulins. The antisera produced contained antikallikrein and also anti-IgG, in spite of only 8% contamination of kallikrein preparation with IgG. The latter antibody was removed by adsorption of antisera with either Fletcher factordeficient plasma or with purified IgG. Both kallikrein and prekallikrein (in plasma) cross-react with the antibody with no apparent difference between the precipitation arcs developed during immunoelectrophoresis and no significant difference in reactivity when quantified by radial immunodiffusion.
INTRODUCTION
Plasma kallikrein is a proteolytic enzyme that releases the nonapeptide bradykinin from the plasma a2-globulin kininogen. Bradykinin, when present systemically in nanogram amouts, profoundly lowers the blood pressure and, when locally injected, mimics many of the features of the inflammatory response (1) . Kallikrein exists in a precursor form, prekallikrein, which is converted to the active protease by factor XIIA (Hageman factor) and its proteolytically produced derivatives (2) (3) (4) (5) . Assays for kallikrein and prekallikrein have been based on the action of the enzyme on synthetic substrates (6) or its ability to release bradykinin (7) . It seemed desirable also to measure prekallikrein immunochemically to observe fluctuations of the protein as well as the enzymatic acitvity in disease and to ascertain whether nonfunctional forms of kallikrein might characterize congential or acquired disorders.
This study describes the further purification of kallikrein (8) and the use of such a preparation and plasma congenitally lacking prekallikrein (9) to obtain a monospecific precipitating antibody to prekallikrein and kallikrein. The interaction of the antibody with prekallikrein is assessed by its ability to inhibit the conversion of prekallikrein to kallikrein and the effect on kallikrein is measured by inhibition of the proteolytic and esterolytic activity of kallikrein. The antibody is also used as a tool to demonstrate complex formation between kallikrein and some of its natural inhibitors. Finally, de- The Journal of Clinical Investigation Volume 54 December 1974-1444-1454plasma proteins, anti-a-macroglobulin (a2-M), anti-Cl-inactivator, and anti-al-antitrypsin (a,-AT) were purchased from Behringwerke AG, Marburg-Lahn, West Germany.
Plasma samples. To obtain human, monkey, rabbit, rat, goat, and dog plasma, nine vol of blood from healthy donors was drawn directly into plastic tubes containing 1 vol of 3.8% citrate and was immediately centrifuged at 2,500 g at 4VC to remove the cells. Plasma was then stored at -70'C. For certain experiments, hexadimethrene bromide was added to the citrate to produce a final concentration of 50 ,g/ml plasma. Factor XII-deficient plasma was obtained from a donor with congenital deficiency of factor XII. Fletcher factor-deficient plasma, which lacks functional and immunochemical kallikrein (9) , from a single donor was a gift from Dr. C Abilgaard, University of California at Davis. Plasma samples were obtained from patients included in a previous study (10) measuring functional kallikrein and bradykinin. The criteria for diagnosis have been described (10) . Patients with prothrombin times more than 3 s from control were considered to have severe disease; those with normal prothrombin times, mild disease.
Protein determination. Protein was determined by absorbance at 280 nm with Em.01% assumed equal to 10. In some cases the method of Groves, David, and Sells (11) or Lowry, Rosebrough, Farr, and Randall (12) was used. Determination of kallikrein and kinin levels. Kallikrein activity was measured either by its arginine esterase activity or by its proteolytic activity. Esterase activity was measured with TAMe by a modification of the method of Siegelman, Carlsen, and Robertsen (13) , which has been described in detail (14) . The proteolytic activity of kallikrein was measured by its ability to release bradykinin from plasma containing 3 mM o-phenanthroline. Kinins were measured by the radioimmunoassay technique (15) .
Further purification of plasma kallikrein. Human kallikrein as prepared according to the procedure of Colman, Mattler, and Sherry (8) was further purified in an attempt to remove the only major contaminant, gamma globulin, by gel filtration on Sephadex G-200, as described in Fig. 1 . The purified preparation was further characterized by polyacrylamide gel electrophoresis (7%), performed according 'Abbreviations used in this paper: a,-AT, ac-antitrypsin; a2-M, ar-macroglobulin; PKA, low molecular weight prekallikrein activators; TAMe, L-tosyl arginine methyl ester. Preparation of activators of prekallikrein. These enzymes were obtained in a partially purified state as a byproduct of kallikrein preparation and further purified as described earlier (4) . Large activator was a single band on analytical polyacrylamide electrophoresis while low molecular weight prekallikrein activators (PKA) was comprised of several bands in the prealbumin region, which all had activator activity.
Preparation of Hageman factor. Factor XII was purified according to the procedure of Cochrane and Wuepper (3) and further eluted off the acrylamide gels (4).
Preparation and assay of gamma globulins. Gamma globulins were by-products of the final step of the kallikrein purification. They were present in the front of the first peak (pool A, Fig. 1 ). Gamma globulin was measured with radial immunodiffusion plates (Behring Diagnostics, Inc., Woodbury, N. Y.).
Isolation of inhibitors of kallikrein from plasma. To separate C1 inactivator, ac-M, and a,-AT from each other, the gel filtration procedure of McConnell (17) was used with some modification, as detailed in Fig. 8 . Eluted fractions were tested for the kallikrein inhibitors by the arginine esterase assay. For this purpose, 0.03 ml purified kallikrein sample (9.3 ,umol TAMe hydrolyzed/ml) was incubated with 0.5 ml of the fractions for 5 min at 25°C, and esterase activity of the mixtures was determined. Fractions were also checked for prekallikrein, with PKA as activator. For this purpose, 0.03 ml PKA was incubated with 0.2 ml of each fraction for 60 S at 25°C. The kallikrein formed was then measured by the TAMe assay.
Antibody production. Purified kallikrein obtained after
Immunochemical Studies of Plasma Kallikrein gel filtration (pool C, Fig. 1 difference in the diameter of the precipitin rings were found after 18 h.
Studies on the interaction of kallikrein or prekallikrein with different plasma inhibitors. A mixture of 0.02 ml of normal plasma and 0.02 ml of purified kallikrein, containing 6-8 jug kallikrein, was incubated for 5 min at 250C. In the case of studies with isolated plasma inhibitors of kallikrein, 0.02 ml of kallikrein was incubated with 0.015 ml of each inhibitor separately for a period of 5 and 30 min at 250C.
The reaction was terminated by the addition of 0.005 ml of 0.1 TAMe solution to the mixture, and 0.02 ml of the mixture was then placed in each of the wells made in 1% agar plates. In the other well was 0.02 ml of the plasmasaline or kallikrein saline mixture. Electrophoresis of the immunoplates was carried out at room temperature for 3 h at 6 mamp/plate. After the run, the center groove was filled with 0.15-0.20 ml of the antiserum against kallikrein or antiserum against kallikrein inhibitors, such as Cf inhibitor, a2-M, and a,-AT. Precipitin arcs were developed overnight at room temperature in a moist chamber.
Statistical analysis of the data obtained on the kallikrein levels in normal and cirrhotic patients. The kallikrein antigen levels in normals and cirrhotic patients were plotted against prekallikrein activities and a regression line was calculated by the method of least squares. The 95% confidence limits were calculated by a standard formula (21) .
RESULTS

Purification of human kallikrein
After filtration through the Sephadex G-200 column ( Fig. 1 ), the esterase activity (peak fraction 92) eluted after the protein peak (peak fraction 76), but some overlaps occur. The first protein peak had an estimated mol wt of 160,000 and was shown to contain over 95% gamma globulin by radial immunodiffusion. Three pools were made, A, B, and C, as indicated in the figure. The specific activity of kallikrein in tube 92 was 24 and the maximum specific activity in tubes comprising pool C was estimated at 40. Pools B and C, both in the region of the esterase peak, revealed 35 and 8% gamma globulin, and the specific activities of arginine esterase after concentration were 9.3 and 10 Imol TAMe hydrolyzed/ min/ml, respectively. The loss of activity was probably due to surface denaturation during concentration, since the addition of bovine serum albumin before concentration increased the activity in the concentrate three-tofourfold.
Purified kallikrein (pool C) was run in acrylamide gels in duplicate (Fig. 2) (Fig. 3, B and C) . The single arc corresponding to the major component of kallikrein was nearer the antigen well (Fig. 3A) .
The specificity of the kallikrein antibody is further confirmed by the Ouchterlony diffusion technique. Both Fletcher factor-adsorbed antibody and IgG-adsorbed antibody show a single line with a reaction of identity with kallikrein.
Species specificity of the kallikrein antibody
After removal of the contaminating anti-IgG from rabbit antiserum, the absorbed antiserum was tested against plasmas from animals as well as from humans. Only human and monkey plasmas reacted against the antibody. 
Distribution of kallikrein antigen
As expected, the kallikrein antigen at different stages of the purification reacted with the antibody (Fig. 4) Effect of the kallikrein antibody on kallikrein activity Table I summarized the inhibition of kallikrein activity by antisera when the esterase activity of kallikrein is measured. A maximum of 53.5% inhibition of kallikrein was obtained when 0.03 ml of the antisera was incubated with 0.02 ml kallikrein (2 Mmol TAMe hydrolyzed/ml/min) for 90 s at 250C (Table I) . Under the same conditions, the normal serum caused 25.5% inhibition. When the bradykinin release by kallikrein was measured, the rabbit antisera caused almost complete inhibition (91.5%) of kallikrein activity, while under the same conditions, normal rabbit sera caused 20.7% inhibition ( Table I ).
Effect of antiserum on the activation of prekallikrein Esterase assay. At an antiserum-to-plasma ratio of 0.2 and incubation time of 60 s at 250C, using PKA as an activator resulted in 50% inhibition with the antisera (Table II) . At the same ratio, large activator in- hibits to a similar degree (59%). In contrast, with factor XIIA 75% inhibition is observed, essentially the same as when kaolin was used to activate prekallikrein (86%). Inhibition with unimmunized normal rabbit sera ranged from 0 to 16%.
Bradykinin assay. Kinin release measurement confirms the pattern of inhibition with different activators. When PKA or large activator was used as an activator, about 24% inhibition of prekallikrein occurred. In the case of factor XIIA, a higher inhibition of 67% was found, similar to that seen with kaolin (54%). The inhibition by antiserum displays a definite concentration dependence, as seen for PKA and kaolin. However, in keeping with the weaker inhibition toward PKA, an antiserum/plasma ratio of 0.5 was required to obtain 95% inhibition, compared to a ratio of 0.3 for kaolin. In these experiments, 850 ng/ml kinin was released in the absence of the antisera. Normal rabbit sera used instead of antisera, as a control, had no inhibitory effect. In contrast, it enhanced the bradykinin levels, probably because of kininogen in the sera (Table II).
Interaction between kallikrein and inhibitors in plasma
Incubation of purified kallikrein with plasma resulted in formation of a new precipitin arc, demonstrated by the immunoelectrophoresis with antiserum against kallikrein (Fig. 5) . In contrast to kallikrein alone or prekallikrein (in plasma), which at pH 8.6 migrate toward the negative pole in the electrical field, the product of the interaction between enzyme and inhibitor remained at the origin. Attempts to identify the inhibitor responsible for this component were made with specific antibodies for each inhibitor. In the absence of kallikrein, C1 inactivator migrated a very short distance toward the positive pole, while ai-AT had the greatest migration and a2-M, intermediate. After incubation of plasma and purified kallikrein, no change in migration or intensity of the precipitin arcs was evident.
Partial purification of kallikrein inhibitors
Gel filtration of normal plasma through Sephadex G-200 resolved the kallikrein inhibitor activities into three completely separate peaks, similar to those obtained by McConnell (17) . The inhibitor activity peak eluting first (peak 1) is a2-M, peak 2 is C1 inactivator, and peak 3 is al-AT (Fig. 6) . The Interaction between kallikrein and partially purified inhibitors
Partially purified plasma inhibitors obtained by gel filtration were separately incubated with purified kallikrein. Immunoelectrophoresis developed with antikallikrein antiserum revealed physical interaction between kallikrein and Cl inactivator (Fig. 7) as evidenced by appearance of a new precipitin arc. No new component was evident with a,-AT or a2-M (Fig. 7) . A marked decrease in the apparent concentration of kallikrein was noted after incubation with partially purified a2-M, but no new arc was noted. Similar precipitin arcs were obtained whether kallikrein was incubated with the in- hibitors for 5 or 30 min. In contrast, using antisera against each of the inhibitors failed to make any difference in either migration or concentration.
Immunochemical estimation of kallikrein levels in plasma Different amounts of purified kallikrein were reacted against absorbed antiserum in radial immunodiffusion plates. A linear relationship between antigen concentration and the square of the diameter of the precipitin rings was found (Fig. 8) Immunochemical estimation of kallikrein in plasma of patients with alcoholic cirrhosis
The 19 normal individual plasmas showed a functional kallikrein activity level of 98±11 SD gmol TAMe hydrolyzed/ml/h which compares with 97±24 reported previously (6) , while the kallikrein antigen had a mean of 103±13 ug/ml. Nine patients with mild alcoholic cirrhosis had a mean prekallikrein activity of 48±412 Amol/ml/h and a mean prekallikrein antigen of 50±8. In 11 patients with severe cirrhosis, the mean prekallikrein activity was 8±9 and the mean antigen was 39±11 (Fig. 9) .
The correlation coefficient for normal subjects was r = 0.87 (P < 0.001) and for mild cirrhosis r = 0.80 (P < 0.01), indicating a highly probable relationship between prekallikrein antigen and activity. The slopes of the regression lines for these two groups and the intercepts do not differ significantly (P > 0.30) and all of the values of the mild cirrhosis lie within the 95% confidence limits of the normal regression line. In contrast, the correlation coefficient for the severe cirrhotics was r = 0.06 (P > 0.80), indicating that the antigen and functional activity of prekallikrein are independent of each other in this group. Furthermore, 5 of 11 of these patient values lie above the regression line for normal.
DISCUSSION
Purification of human plasma kallikrein has been a challenging problem, because of the close resemblance of kallikrein to other plasma proteases and to '-globulin. Harpel (22) was unable to separate the kallikrein from factor XI by isoelectric focusing, acrylamide gel electrophoresis, or G-200 Sephadex. Schreiber, Kaplan, and Austen (23) found that the isoelectric points of kallikrein, plasminogen proactivator, and factor XI are a few tenths pH apart and a kallikrein preparation demonstrated a broad band from pH 7.5 to 8.9 after focusing (24) . Prekallikrein purified by Kaplan, Kay, and Austen (24) contained IgG as detected by radial immunodiffusion. Similar problems have been encountered in this laboratory. When highly purified plasma kallikrein was prepared (8) and subjected to acrylamide gel electrophoresis, one broad band was found. The properties of the kallikrein in this preparation agreed with those found by other workers. The enzyme has a molecular weight of approximately 100,000 (8), migrates electrophoretically as gamma globulin, releases kinin from heated plasma (61°C for 2 h), displays arginine esterase activity, and is inhibited by soybean trypsin inhibitor, diisopropylphosphofluoridate, C1 esterase inhibitor, and a2-M. However, gamma globulin was later detected in the kallikrein I preparation, although no C1 Wuepper (9) has shown that a congenital coagulation disorder known as Fletcher factor deficiency is due to a lack of prekallikrein, as measured functionally and immunologically. After adsorption of the antibody preparation with Fletcher factor-deficient plasma, a single pre-cipitin arc identical to that demonstrated with the antibody adsorbed with gamma globulin was observed. The observation suggests that the only other major component in the kallikrein preparation was gamma globulin and that the remaining antibody after either adsorption was directed against kallikrein. The adsorbed kallikrein antibody was then examined to see if it could detect prekallikrein in plasma. By immunoelectrophoresis, identical migration was found for purified kallikrein and prekallikrein in plasma that contained hexadimethrine to prevent activation. Moreover, the residual antibody reacted with human plasma kallikrein at all stages of purification despite varying degrees of activation (8), giving a reaction of identity by immunodiffusion. Further, antiserum precipitated the kallikrein antigen from plasma, neutralized kallikrein activity, and inhibited prekallikrein activation. These properties provide evidence that this antibody is directed against antigenic determinants present on both kallikrein and prekallikrein. Although no precipitin reaction was noted with dog, goat, sheep, cow, rabbit, or rat plasma, monkey plasma reacted with the antihuman kallikrein antibody and showed a line of identity with human plasma expected from the close evolutionary relationship.
In many cases, antibodies directed against enzymes do inhibit their respective antigens' catalytic action; i.e. they are neutralizing antibodies. When kallikrein was incubated with the antiserum, only a partial inhibition (30%) was observed for the esterolytic activity of the enzyme, yet the antisera inhibited 91.5% of the kallikrein proteolytic activity. The incomplete inhibition of esterolytic activity is similar to the observations by Harpel (25) that enzymes which interact with a2-M, e.g. thrombin (26) , kallikrein (27, 17) , and trypsin (28), form a complex in which the enzymes retain their ability to degrade low molecular weight substrates while their proteolytic activity is lost. In contrast, Cd inactivator inhibits the proteolytic and esterolytic actions of kallikrein equally (23, 29 (Fig. 5) with antikallikrein antibody indicate that kallikrein incubated with plasma produces a new species distinct from free kallikrein but with migration similar to Cl inactivator, detected by a specific antibody. To identify which inhibitor was responsible for the formation of the interaction product, each inhibitor, after partial purification by gel filtration, was separately interacted with purified kallikrein. Only the preparation containing C1 inactivator formed a new precipitation arc with kallikrein. This component may represent a complex between the enzyme and inhibitor or an altered kallikrein. Further experiments are needed to clarify the nature of this component. Similar interaction products may be formed in vivo during activation of this system.
Formation of a complex between purified kallikrein and a2-M, either partially purified or as present in normal plasma, could not definitely be demonstrated by immunoelectrophoresis with either antikallikrein or antia2-M. However, the product of the interaction between kallikrein (mol wt 90,000) and a2-M (mol wt 700,000) might have identical electrical mobility to that of the free a2-M, as has been seen with chymotrysin (31) . When the mixture of kallikrein and partially purified a2-M were subjected to immunoelectrophoresis and the plates developed with antikallikrein, a marked decrease in the strength of the precipitin line is observed (Fig.  7) . This finding suggests that part of the kallikrein has been bound by a2-M, thus diminishing the concentration of free kallikrein. However, the complexed kallikrein is not detected by the kallikrein antibody, probably because of decreased availability of antigenic site in the complex.
It is generally agreed that CT inactivator is a major inhibitor of kallikrein in plasma and that a2-M also inhibits kallikrein, and especially its proteolytic activity (17, 23, 27) . Whether a,-AT is also an inhibitor of kallikrein is controversial (32, 23) . McConnell (17) , using the three inhibitors separated from normal plasma by gel filtration, demonstrated inhibition by both Cl inactivator and a2-M of kallikrein proteolytic activity and also weak inhibition by al-AT. In the present investigation, the percent of the total plasma inhibitory capacity for kallikrein esterase activity was calculated to be 68.5% for Cl inactivator, 13.7% for a2-M, and 17.8% for al-AT. In our study, as well as in that of McConnell, the a2-M is a relatively poor inhibitor of esterase activity of kallikrein (25) . Harpel has documented that kallikrein can cleave a2-M, presumably allowing subsequent complex formation between inhibitor and enzyme (25) .
The preparation of the antibody to kallikrein made possible the development of a radial immunodiffusion assay for plasma kallikrein antigen, which is present in noncontacted plasma as prekallikrein. The specificity of the assay is evident, since Fletcher factor-deficient plasma contained no kallikrein antigen when IgG-absorbed antibody was used. In contrast, Hageman factordeficient plasma gave a value in the range of normal.
Liver disease results in markedly decreased prekallikrein activity (4, 15) . This finding might be due to decreased function of an abnormal prekallikrein or an absolute decrease in the amount of prekallikrein synthesized. There has been some evidence indicating that the liver is the site for plasma prekallikrein biosynthesis (10, 33) . Depression of plasma prekallikrein in hepatocellular disease has been documented (6, 10) . In mild alcholic cirrhosis, functional and antigenic kallikrein are significantly depressed and closely correlated. The relationship between antigen and esterase activity is similar to that in normal subjects. However, the plasma of patients with severe liver disease in whom levels of prekallikrein have been decreased to 8% of normal, as measured by esterase assay, contain about 40% of the normal prekallikrein antigen (Fig. 9) . The absence of the correlation between kallikrein function and antigen in severe liver disease suggests that although synthesis is depressed, the livers of some of these patients may be synthesizing a nonfunctional kallikrein. Examination of the prekallikrein antigen present in the plasma from one of the severe cirrhosis patients revealed a weak precipitin arc. However, no significant difference in the position of the arc after immunoelectrophoresis was noted when compared to normal plasma.
